Clinical Trial Update: Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Congestive Heart Failure, Type II Diabetes Mellitus | Phase 4 | Status: COMPLETED